These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
924 related articles for article (PubMed ID: 18853980)
1. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Chan FK; Abraham NS; Scheiman JM; Laine L; Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980 [TBL] [Abstract][Full Text] [Related]
2. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Rostom A; Moayyedi P; Hunt R; Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986 [TBL] [Abstract][Full Text] [Related]
3. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Scheiman JM; Hindley CE Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236 [TBL] [Abstract][Full Text] [Related]
4. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Hur C; Chan AT; Tramontano AC; Gazelle GS Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709 [TBL] [Abstract][Full Text] [Related]
5. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. Tannenbaum H; Bombardier C; Davis P; Russell AS; J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802 [TBL] [Abstract][Full Text] [Related]
6. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Targownik LE; Metge CJ; Leung S; Chateau DG Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634 [TBL] [Abstract][Full Text] [Related]
8. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Lanas A; Ferrandez A Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792 [TBL] [Abstract][Full Text] [Related]
9. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Lanas A; Hunt R Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305 [TBL] [Abstract][Full Text] [Related]
10. NSAIDs-induced gastrointestinal damage. Review. Arroyo M; Lanas A Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869 [TBL] [Abstract][Full Text] [Related]
11. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558 [TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Laine L Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966 [TBL] [Abstract][Full Text] [Related]
15. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798 [TBL] [Abstract][Full Text] [Related]
16. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133 [TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747 [TBL] [Abstract][Full Text] [Related]
18. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797 [TBL] [Abstract][Full Text] [Related]